UnitedHealth Group / EMIS merger inquiry

The CMA is investigating the anticipated acquisition by UnitedHealth Group Incorporated, via Bordeaux UK Holdings II Limited, of EMIS Group Plc.

From:
Competition and Markets Authority
Published
20 January 2023
Last updated
29 September 2023 — See all updates
Case type:
Mergers
Case state:
Closed
Market sector:
Healthcare and medical equipment
Outcome:
Mergers - phase 2 clearance
Opened:
20 January 2023
Closed:
29 September 2023

Phase 2

Administrative timetable

Date of referral: 31 March 2023

Statutory deadline: 5 October 2023

Contact

[email protected]

Final report

29 September 2023: The CMA has published its final report.

Responses to provisional findings

Provisional findings

11 August 2023: The CMA has provisionally cleared the anticipated acquisition by UnitedHealth Group Incorporated of EMIS Group Plc.

The deadline for submitting responses to the provisional findings is 5pm on Friday 1 September 2023.

Response to the issues statement

Issues statement

17 May 2023: The issues statement sets out the scope of the inquiry. It outlines initial theories on what might be adversely affecting competition, but it does not set out findings or conclusions.

Notice of extension

Inquiry group appointed

31 March 2023: The CMA has appointed the inquiry group. Kirstin Baker (Chair), Ulrike Hotopp, Frances McLeman and Sir Kenneth Parker.

Terms of reference

31 March 2023: The CMA has referred the anticipated acquisition by UnitedHealth Group Incorporated of EMIS Group Plc for an in-depth investigation.

Phase 1

Statutory timetable

Date Action
17 March 2023 Decision announced
20 January 2023 Launch of merger inquiry
20 January 2023 to 3 February 2023 Invitation to comment

Reference decision

31 March 2023: The CMA has referred the anticipated acquisition by UnitedHealth Group Incorporated of EMIS Group Plc for an in-depth investigation, on the basis that, on the information currently available to it, it is or may be the case that this merger has resulted or may be expected to result in a substantial lessening of competition within a market or markets in the United Kingdom.

Reference unless undertakings accepted

17 March 2023: The CMA has decided, on the information currently available to it, that it is or may be the case that this merger may be expected to result in a substantial lessening of competition within a market or markets in the United Kingdom. This merger will be referred for a phase 2 investigation unless the parties offer acceptable undertakings to address these competition concerns.

Launch of merger inquiry

20 January 2023: The CMA announced the launch of its merger inquiry by notice to the parties.

Invitation to comment: closed

20 January 2023: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2022 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.

To assist it with this assessment, the CMA invites comments on the transaction from any interested party.

These comments should be provided by the deadline set out above.

Contact

Please send written representations about any competition or public interest issues to:

[email protected]

Updates to this page

Published 20 January 2023
Last updated 29 September 2023 + show all updates

  1. Final report, appendices and glossary published

  2. Summary of final report published

  3. Responses to the provisional findings published.

  4. Provisional findings and Appendices and glossary published

  5. Provisional findings published

  6. Phase 1 full text decision, Decision to refer, Issues statement and Administrative timetable published.

  7. Notice of extension published.

  8. Inquiry group appointed and terms of reference published.

  9. Reference decision announced.

  10. Summary of the Phase 1 decision published

  11. First published.

Contents